Liqun Yang
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Liqun Yang has a total of 31 co-authors. Here are the top co-authors by number of shared publications:
- Adam Grippin
Department of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, USA
1 shared publication Andreanne Poppy Estania
School of Chemical Biology and Biotechnology, Peking University Shenzhen Graduate School, Shenzhen, China
1 shared publication- Andrew S. Lee
School of Chemical Biology and Biotechnology, Peking University Shenzhen Graduate School, Shenzhen, China
1 shared publication - Annette Wu
Department of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA
1 shared publication - Betty Yon Son Kim
Department of Neurosurgery, The University of Texas MD Anderson Cancer Center, Houston, USA
1 shared publication Eman Bahrani
Departments of Dermatology and Pathology, Vanderbilt University Medical Center, Nashville, TN, USA
1 shared publication
Latest Publications
- Top Cited Papers
- 11 June 2026
- Published by Springer Nature in Nature Biomedical Engineering
Skeletal-muscle-targeted non-viral delivery of full-length DMD mRNA for Duchenne muscular dystrophy
Duchenne muscular dystrophy (DMD) is a severe, progressive muscle-wasting disorder caused by mutations in the DMD gene, which encodes dystrophin. Although gene therapy using viral vectors has shown promise for the treatment of DMD, the clinical application of viral gene therapies is limited by vector toxicity, immunogenicity and the inability to package full-length dystrophin. Recent advances in messenger RNA (mRNA) technology offer a non-integrating, transient approach to restoring protein expression. Here we report the systemic delivery of skeletal-muscle-targeted full-length DMD mRNA in a murine model of DMD using allogenically engineered targeting extracellular vesicles (DMD t-EVs). This approach restores the endogenous translation of wild-type dystrophin and substantially improves muscle function. We further demonstrate the safety and biocompatibility of DMD t-EVs in non-human primates, supporting their translational potential. These findings highlight the promise of mRNA-loaded extracellular vesicles as a therapeutic platform for treating genetic disorders involving large, difficult-to-package genes.
- 11 June 2026
- Published by Springer Nature in Nature Biomedical Engineering
Top Cited PapersSkeletal-muscle-targeted non-viral delivery of full-length DMD mRNA for Duchenne muscular dystrophy
Duchenne muscular dystrophy (DMD) is a severe, progressive muscle-wasting disorder caused by mutations in the DMD gene, which encodes dystrophin. Although gene therapy using viral vectors has shown promise for the treatment of DMD, the clinical application of viral gene therapies is limited by vector toxicity, immunogenicity and the inability to package full-length dystrophin. Recent advances in messenger RNA (mRNA) technology offer a non-integrating, transient approach to restoring protein expression. Here we report the systemic delivery of skeletal-muscle-targeted full-length DMD mRNA in a murine model of DMD using allogenically engineered targeting extracellular vesicles (DMD t-EVs). This approach restores the endogenous translation of wild-type dystrophin and substantially improves muscle function. We further demonstrate the safety and biocompatibility of DMD t-EVs in non-human primates, supporting their translational potential. These findings highlight the promise of mRNA-loaded extracellular vesicles as a therapeutic platform for treating genetic disorders involving large, difficult-to-package genes.